MedTrace Logo

Safety Study of BMS-770767 in Subjects With Type 2 Diabetes

NCT01046422 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 76

Last updated 2015-10-12

No results posted yet for this study

Summary

The purpose of this study is to determine if BMS-770767 is safe, well tolerated, measure its levels in the blood (pharmacokinetics), and measure the levels of chemicals (biomarkers) that may be affected by this drug (pharmacodynamics) in a type 2 diabetes patient population

Conditions

  • Diabetes Type 2

Interventions

DRUG

BMS-770767

Capsule, Oral, 15mg, Active, Daily, 28 days

DRUG

BMS-770767

Capsule, Oral, 50mg, Active, Daily, 28 days

DRUG

BMS-770767

Capsule, Oral, 150mg, Active, Daily, 28 days

DRUG

BMS-770767

Capsule, Oral, 50mg BID, Active, Daily, 28 days

DRUG

Placebo

Capsule, Oral, 0mg, Daily, 28 days

DRUG

Metformin

Tablet, Oral, ≥ 1500mg, Active, Daily, 28 days

Sponsors & Collaborators

Principal Investigators

  • Bristol-Myers Squibb · Bristol-Myers Squibb

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-05-31
Primary Completion
2011-01-31
Completion
2011-01-31

Countries

  • United States
  • Australia
  • Canada
  • South Korea

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01046422 on ClinicalTrials.gov